WallStSmart

Boston Scientific Corp (BSX)vsVicarious Surgical Inc. (RBOT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BSX leads profitability with a 14.4% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

RBOT

Avoid

29

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for RBOT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

RBOT1 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

RBOT4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.84M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : RBOT

The strongest argument for RBOT centers on Price/Book.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : RBOT

The primary concerns for RBOT are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BSX profiles as a growth stock while RBOT is a value play — different risk/reward profiles.

RBOT carries more volatility with a beta of 1.55 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 29/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Vicarious Surgical Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Vicarious Surgical Inc. (RBOT) is an innovative medical technology company focused on transforming surgical practices through its state-of-the-art robotic surgical systems that enhance precision and improve patient outcomes. By combining advanced robotics with artificial intelligence, Vicarious Surgical is pioneering a new era of minimally invasive surgery, offering surgeons superior dexterity, visualization, and control. The company's proprietary platform not only enhances surgical efficiency but also strives to minimize patient recovery times, thereby responding to the increasing demand for robotic-assisted procedures. As a leader in the rapidly growing surgical robotics market, Vicarious Surgical is dedicated to advancing patient care and addressing the evolving challenges within the healthcare sector.

Want to dig deeper into these stocks?